


COAPT-QoL: Health Status After Transcatheter Mitral Valve Repair in Patients With Heart Failure and Secondary Mitral Regurgitation



AMERICAN COLLEGE of CARDIOLOGY

Multicenter, double-blind, parallel-group, randomized controlled trial

Objective: To understand the health status outcomes of patients with HF and 3-4+ secondary MR treated with TMVR versus standard care.



Patients with HF and secondary MR



TMVR vs. standard care



Clinical outcomes



614 patients with HF and 3-4+ secondary MR were randomized to:



TMVR
(n=302)



Standard care
(n=312)



Primary Outcomes

**KCCQ overall summary score
(KCCQOS range 0-100; higher=better)**

Mean difference 15.9 points, 95% CI 12.3 to 19.5

36.4%

Patients with ≥ 10 -point improvement at 24 months

16.6%

$p < 0.001$

SF-36 summary scores

(24-month mean difference in SF-36 summary scores: physical 3.6 points, 95% CI 1.4-5.8; mental 3.6 points, 95% CI 0.8-6.4)

Among patients with symptomatic HF and 3-4+ secondary MR receiving maximally-tolerated medical therapy, TMVR resulted in substantial early and sustained health status improvement compared with medical therapy alone.